David Miller - Wayland Group Chief Officer
| MRRCF Stock | USD 0.0001 0.00 0.00% |
Insider
David Miller is Chief Officer of Wayland Group Corp
| Phone | 289-288-6274 |
| Web | https://www.waylandgroup.com |
David Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Miller against Wayland Group pink sheet is an integral part of due diligence when investing in Wayland Group. David Miller insider activity provides valuable insight into whether Wayland Group is net buyers or sellers over its current business cycle. Note, Wayland Group insiders must abide by specific rules, including filing SEC forms every time they buy or sell Wayland Group'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Miller over two months ago Acquisition by David Miller of tradable shares of Murphy USA subject to Rule 16b-3 | ||
David Miller over six months ago Acquisition by David Miller of 3756 shares of Ellington Residential subject to Rule 16b-3 |
Wayland Group Management Efficiency
The company has return on total asset (ROA) of (0.2952) % which means that it has lost $0.2952 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6106) %, meaning that it generated substantial loss on money invested by shareholders. Wayland Group's management efficiency ratios could be used to measure how well Wayland Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sibyl Swift | cbdMD Inc | 43 | |
| John Weston | cbdMD Inc | N/A | |
| Amos Cohen | INC Research Holdings | 45 | |
| David Erickson | Evolus Inc | N/A | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Mark Baldyga | Biofrontera | N/A | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Raymond Coffman | cbdMD Inc | 62 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Thomas Flow | Akanda Corp | 46 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Hermann Lubbert | Biofrontera | 68 | |
| Eugene III | Biofrontera | 39 | |
| Advocate Ohayon | INC Research Holdings | 35 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Jeff Holm | Biofrontera | N/A | |
Management Performance
| Return On Equity | -0.61 | |||
| Return On Asset | -0.3 |
Wayland Group Corp Leadership Team
Elected by the shareholders, the Wayland Group's board of directors comprises two types of representatives: Wayland Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wayland. The board's role is to monitor Wayland Group's management team and ensure that shareholders' interests are well served. Wayland Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wayland Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raymond Stone, Sec | ||
| Geoff Kosar, Vice President - Sales and Marketing | ||
| James Hyssen, Chief Officer | ||
| Shawn Alexander, VP Relations | ||
| Steven Bennett, Chief Officer | ||
| David Miller, Chief Officer | ||
| Graham Farrell, VP Communications |
Wayland Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Wayland Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (16.12) % | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 139.88 M | |||
| Shares Owned By Insiders | 1.82 % | |||
| Shares Owned By Institutions | 7.03 % | |||
| Price To Earning | (1.16) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 2.92 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Wayland Pink Sheet
Wayland Group financial ratios help investors to determine whether Wayland Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wayland with respect to the benefits of owning Wayland Group security.